Rob A. A. van Kollenburg
Papers
2
Total Citations
38
H-Index
2
About
Rob A. A. van Kollenburg is a pioneering urological researcher whose work centers on advancing minimally invasive treatments for prostate cancer, with a particular focus on focal laser ablation (FLA) therapies. His major contributions lie in establishing the safety, feasibility, and clinical efficacy of Soractelite™ transperineal focal laser ablation (TPLA) for localized prostate cancer—a novel technique designed to precisely ablate cancerous tissue while preserving healthy surrounding structures and minimizing treatment-related morbidity. In his highly cited 2022 multicenter pilot study (24 citations), van Kollenburg demonstrated that TPLA offers favorable short-term quality of life outcomes compared to traditional radical therapies. Building on this, his 2023 work (14 citations) provided critical insights into reliable post-treatment visualization using magnetic resonance imaging and contrast-enhanced ultrasound, addressing the lack of a standardized dosimetry model for TPLA. By mapping three-dimensional histologically defined ablation zones, van Kollenburg has helped pave the way for more predictable and effective focal treatments. His research is instrumental in shifting the prostate cancer treatment paradigm toward organ-sparing approaches, offering patients a promising alternative with reduced side effects.
Research Focus
Key Achievements
Top Papers
- 1
- 2